HUSCAP logo Hokkaido Univ. logo

Hokkaido University Collection of Scholarly and Academic Papers >
Faculty of Pharmaceutical Sciences >
Peer-reviewed Journal Articles, etc >

リネゾリド投与患者における嘔吐発現の因果関係の検証

Files in This Item:

The file(s) associated with this item can be obtained from the following URL:https://doi.org/10.1248/yakushi.19-00010


Title: リネゾリド投与患者における嘔吐発現の因果関係の検証
Other Titles: Verification of Relationship between Administration of Linezolid and Vomiting
Authors: 堤, 竹蔵1 Browse this author
今井, 俊吾2 Browse this author
山田, 勝久3 Browse this author
山田, 武宏4 Browse this author
笠師, 久美子5 Browse this author
小林, 正紀6 Browse this author →KAKEN DB
井関, 健7 Browse this author →KAKEN DB
Authors(alt): Tsutsumi, Takezo1
Imai, Shungo2
Yamada, Katsuhisa3
Yamada, Takehiro4
Kasashi, Kumiko5
Kobayashi, Masaki6
Iseki, Ken7
Keywords: linezolid
vomiting
adverse drug reaction
Issue Date: Jul-2019
Publisher: 日本薬学会
Journal Title: 薬学雑誌
Journal Title(alt): Journal of the pharmaceutical society of Japan
Yakugaku zasshi
Volume: 139
Issue: 7
Start Page: 1055
End Page: 1061
Publisher DOI: 10.1248/yakushi.19-00010
Abstract: Linezolid (LZD), an antimicrobial agent against methicillin-resistant Staphylococcus aureus, demonstrates good bone and joint penetration, and is used for prosthetic bone and joint infections. Recently, we observed vomiting in several patients administered LZD. However, there are few reports on the incidence rate of, and risk factors for, LZD-induced nausea and vomiting. In this study, we aimed to verify the relationship between LZD administration and vomiting. Patients administered LZD at the Department of Orthopedic Surgery of Hokkaido University Hospital between November 2008 and December 2017 were enrolled in the study. The primary endpoint was the comparison of the vomiting rate between patients administered LZD (LZD group) and those administered other antibiotics (non-LZD group). For the secondary endpoint, to verify the risk factors of vomiting, a univariate logistic regression analysis was performed. In total, 130 patients were included in this study; 77 patients in the LZD group, and 53 in the non-LZD group. Vomiting occurred in 18 patients in the LZD group and 4 patients in the non-LZD group (23.4% and 7.5%, respectively); this was significantly higher in the LZD group. In the univariate logistic regression analysis, LZD administration, gender (female), age 65 years, renal impairment (creatinine clearance < 60 mL/min) and concomitant use of rifampicin were extracted as potential risk factors of vomiting. The results of this study reveal a possible relationship between LZD administration and vomiting.
Rights: Copyright 2019 The Pharmaceutical Society of Japan
Type: article
URI: http://hdl.handle.net/2115/75193
Appears in Collections:薬学研究院 (Faculty of Pharmaceutical Sciences) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)

Export metadata:

OAI-PMH ( junii2 , jpcoar )


 

Feedback - Hokkaido University